Additionally, the 36-month beta value for PYXS is 1.11. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for PYXS is 42.26M and currently, short sellers hold a 16.57% ratio of that float. The average trading volume of PYXS on February 26, 2025 was 888.13K shares.
PYXS) stock’s latest price update
Pyxis Oncology Inc (NASDAQ: PYXS)’s stock price has soared by 3.75 in relation to previous closing price of 1.20. Nevertheless, the company has seen a loss of -7.78% in its stock price over the last five trading days. globenewswire.com reported 2025-02-26 that Designation applies to the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) whose disease has progressed following treatment with platinum-based chemotherapy and an anti-PD-(L)1 antibody Designation applies to the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) whose disease has progressed following treatment with platinum-based chemotherapy and an anti-PD-(L)1 antibody
PYXS’s Market Performance
Pyxis Oncology Inc (PYXS) has experienced a -7.78% fall in stock performance for the past week, with a -20.70% drop in the past month, and a -40.71% drop in the past quarter. The volatility ratio for the week is 6.14%, and the volatility levels for the past 30 days are at 6.54% for PYXS. The simple moving average for the past 20 days is -9.86% for PYXS’s stock, with a -58.18% simple moving average for the past 200 days.
Analysts’ Opinion of PYXS
Stephens, on the other hand, stated in their research note that they expect to see PYXS reach a price target of $13. The rating they have provided for PYXS stocks is “Overweight” according to the report published on November 08th, 2024.
Stifel gave a rating of “Buy” to PYXS, setting the target price at $10 in the report published on August 08th of the previous year.
PYXS Trading at -17.37% from the 50-Day Moving Average
After a stumble in the market that brought PYXS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -81.82% of loss for the given period.
Volatility was left at 6.54%, however, over the last 30 days, the volatility rate increased by 6.14%, as shares sank -18.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -21.88% lower at present.
During the last 5 trading sessions, PYXS fell by -6.25%, which changed the moving average for the period of 200-days by -70.36% in comparison to the 20-day moving average, which settled at $1.3823. In addition, Pyxis Oncology Inc saw -20.19% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PYXS starting from Connealy Pamela Ann, who purchase 88,850 shares at the price of $1.96 back on Nov 26 ’24. After this action, Connealy Pamela Ann now owns 1,199,143 shares of Pyxis Oncology Inc, valued at $174,364 using the latest closing price.
Stock Fundamentals for PYXS
Current profitability levels for the company are sitting at:
- -3.43 for the present operating margin
- 0.85 for the gross margin
The net margin for Pyxis Oncology Inc stands at -2.93. The total capital return value is set at -0.38. Equity return is now at value -39.34, with -30.03 for asset returns.
Based on Pyxis Oncology Inc (PYXS), the company’s capital structure generated 0.12 points at debt to capital in total, while cash flow to debt ratio is standing at -2.61. The debt to equity ratio resting at 0.13. The interest coverage ratio of the stock is -39.25.
Currently, EBITDA for the company is -78.49 million with net debt to EBITDA at -0.13. When we switch over and look at the enterprise to sales, we see a ratio of 4.22. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.33.
Conclusion
In conclusion, Pyxis Oncology Inc (PYXS) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
